Minnema Monique C, Nasserinejad Kazem, Hegenbart Ute, Ypma Paula F, Wu Ka Lung, Kersten Marie Jose, Croockewit Sandra, Zweegman Sonja, Tick Lidwine, Broijl Annemiek, Koene Harry, Bos Gerard M J, Sonneveld Pieter, Schönland Stefan O
Department of Hematology UMC Utrecht University Utrecht Utrecht The Netherlands.
Department of Hematology HOVON Data Center Erasmus MC Cancer Institute Rotterdam The Netherlands.
EJHaem. 2024 Jun 17;5(4):815-819. doi: 10.1002/jha2.918. eCollection 2024 Aug.
The HOVON 104 studied bortezomib-dexamethasone induction therapy and autologous stem cell transplantation in 50 patients, of whom 35 received an autologous stem cell transplantation (ASCT). We demonstrate a 5-year overall survival (OS) of 73% and progression-free survival (PFS) of 52% for all 50 patients with a median follow-up of 61.3 months. For the 35 transplanted patients, calculated from the date of ASCT, the 5-year OS and PFS were 91% and 68%, respectively. After ASCT, the rate of organ response improved over time but stabilized around 3 years. A complete cardiac response was seen in around 60% of patients and remained stable from 2 years onward. Reaching complete renal response was slower over time and achieved by 61% of the renal-affected patients at 5 years. We confirm the excellent outcomes after ASCT and demonstrate a 60% complete organ response with longer follow-up.
HOVON 104研究了50例患者接受硼替佐米-地塞米松诱导治疗及自体干细胞移植，其中35例接受了自体干细胞移植（ASCT）。我们证明，50例患者的5年总生存率（OS）为73%，无进展生存率（PFS）为52%，中位随访时间为61.3个月。对于35例移植患者，从ASCT日期算起，5年OS和PFS分别为91%和68%。ASCT后，器官反应率随时间改善，但在3年左右稳定下来。约60%的患者出现完全心脏反应，从2年起保持稳定。随着时间推移，达到完全肾脏反应较慢，5年时61%的肾脏受累患者实现了完全肾脏反应。我们证实了ASCT后的良好结果，并通过更长时间的随访证明了60%的完全器官反应。
